Epizyme Inc (EPZM) 21.58 $EPZM
Excitement For Epizyme
Sagar Joshi - at Seeking Alpha - Tue Feb 10, 5:21PM CST
PFE: 34.64 (-0.23), EPZM: 21.58 (+0.08)
Epizyme, Inc. to Present at Upcoming Conferences in February
Business Wire - Thu Feb 05, 7:02AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming conferences in February:
EPZM: 21.58 (+0.08)
New finance chief at Epizyme
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:22AM CST
EPZM: 21.58 (+0.08)
Epizyme Appoints Andrew Singer as Chief Financial Officer
Business Wire - Tue Feb 03, 7:01AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew Singer will join the Company as Chief Financial Officer on February 9th. Mr. Singer brings nearly 20 years of financial experience in the life sciences field and was previously Managing Director, Healthcare Investment Banking, in the Life Sciences Group at RBC Capital Markets Corporation, part of RBC Financial Group.
EPZM: 21.58 (+0.08)
Epizyme Appoints Robert A. Copeland, Ph.D., as President of Research
Business Wire - Thu Jan 29, 7:50AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Robert A. Copeland, Ph.D., has been named President of Research. Dr. Copeland, who was previously Executive Vice President of Research and Chief Scientific Officer at Epizyme, will continue to serve as Chief Scientific Officer.
EPZM: 21.58 (+0.08)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 90.70 (+0.93), ACT: 285.37 (+3.71), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), EPZM: 21.58 (+0.08), ALKS: 71.40 (-1.89), HSP: 87.35 (unch), CELG: 115.88 (+0.16), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17)
Epizyme: The Ugly Duckling Of The 2014 Biotech Rally?
Matija Snuderl - at Seeking Alpha - Fri Jan 02, 8:04AM CST
EPZM: 21.58 (+0.08)
Commit To Purchase Epizyme At $15, Earn 11.5% Annualized Using Options
at The Street - Wed Dec 31, 10:43AM CST
Investors eyeing a purchase of Epizyme Inc. stock, but tentative about paying the going market price of $18.73/share, might benefit from considering selling puts among the alternative strategies at their disposal.
EPZM: 21.58 (+0.08)
Epizyme: Shares Oversold On Mixed Data From Early Studies
Poonam A. Arora - at Seeking Alpha - Tue Dec 30, 7:21AM CST
EPZM: 21.58 (+0.08)
Epizyme selects Kenneth Bate to board
M2 - Mon Dec 15, 5:49AM CST
Biopharmaceutical company Epizyme (NasdaqGS:EPZM) revealed on Friday that Kenneth Bate has been named to its board of directors.
EPZM: 21.58 (+0.08), GNCA: 8.93 (-0.07)
Epizyme Elects Kenneth Bate to Board of Directors
Business Wire - Fri Dec 12, 3:01PM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Kenneth Bate, an independent consultant in the biotechnology industry, has been elected to the Company's board of directors.
EPZM: 21.58 (+0.08)
Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial
Business Wire - Mon Dec 08, 12:30PM CST
--Additional biological activity observed: Resolution of cutaneous leukemia in two patients, leukemia cell differentiation effects in eight patients
EPZM: 21.58 (+0.08)
Epizyme First-in-Class PRMT5 Inhibitor Demonstrates In Vitro and In Vivo Activity in Models of Mantle Cell Lymphoma
Business Wire - Mon Dec 08, 12:30PM CST
--First arginine methyltransferase (RMT) inhibitor to show in vitro and in vivo activity in pre-clinical models of mantle cell lymphoma (MCL)
EPZM: 21.58 (+0.08)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43), OMED: 26.06 (+0.30), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), EPZM: 21.58 (+0.08), AGIO: 118.55 (+0.11), SNY: 49.42 (+0.82), FOLD: 8.36 (-0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Epizyme to Webcast Company Presentation at American Society of Hematology (ASH) Annual Meeting on December 8, 2014
Business Wire - Wed Dec 03, 7:30AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a live audio webcast of its discussion of the Company's clinical programs and pipeline at the ASH annual meeting on Monday, December 8, 2014, at 12:30 p.m. PT (3:30 p.m. ET).
EPZM: 21.58 (+0.08)
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
at The Street - Wed Nov 26, 5:00AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
BLUE: 90.70 (+0.93), OREX: 5.55 (+0.10), BCRX: 10.06 (-0.09), ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), EPZM: 21.58 (+0.08), AGIO: 118.55 (+0.11), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), ENTA: 33.30 (-0.44)
Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 5:15PM CST
Epizyme, Inc. (EPZM) announced positive phase I study data on its oncology candidate, EPZ-6438 for advanced solid tumors and B-cell non-Hodgkin lymphomas.
CYTK: 7.78 (+1.29), BIIB: 391.66 (-0.45), EPZM: 21.58 (+0.08)
Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor
Business Wire - Wed Nov 19, 5:01PM CST
--Ongoing partial response seen in one malignant rhabdoid tumor patient, one of two evaluable solid tumor patients with INI1-deficient tumors
EPZM: 21.58 (+0.08)
Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 5.83 (+0.22), TNGO: 12.11 (+0.42), ENPH: 15.15 (+0.37), PRSC: 39.60 (-0.62), MTRX: 19.92 (+0.77), EPZM: 21.58 (+0.08), CHUY: 22.04 (-0.35), AMRI: 16.94 (-0.28), ANDE: 45.11 (+0.71), SNMX: 5.92 (+0.26), ZU: 14.22 (-0.30)
Epizyme drops after cancer drug data underwhelms
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:35AM CST
EPZM: 21.58 (+0.08)
Excitement For Epizyme
Sagar Joshi - at Seeking Alpha - Tue Feb 10, 5:21PM CST
PFE: 34.64 (-0.23), EPZM: 21.58 (+0.08)
Epizyme, Inc. to Present at Upcoming Conferences in February
Business Wire - Thu Feb 05, 7:02AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming conferences in February:
EPZM: 21.58 (+0.08)
New finance chief at Epizyme
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:22AM CST
EPZM: 21.58 (+0.08)
Epizyme Appoints Andrew Singer as Chief Financial Officer
Business Wire - Tue Feb 03, 7:01AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Andrew Singer will join the Company as Chief Financial Officer on February 9th. Mr. Singer brings nearly 20 years of financial experience in the life sciences field and was previously Managing Director, Healthcare Investment Banking, in the Life Sciences Group at RBC Capital Markets Corporation, part of RBC Financial Group.
EPZM: 21.58 (+0.08)
Epizyme Appoints Robert A. Copeland, Ph.D., as President of Research
Business Wire - Thu Jan 29, 7:50AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Robert A. Copeland, Ph.D., has been named President of Research. Dr. Copeland, who was previously Executive Vice President of Research and Chief Scientific Officer at Epizyme, will continue to serve as Chief Scientific Officer.
EPZM: 21.58 (+0.08)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 90.70 (+0.93), ACT: 285.37 (+3.71), AMGN: 153.48 (+0.30), RGLS: 16.85 (-0.13), EPZM: 21.58 (+0.08), ALKS: 71.40 (-1.89), HSP: 87.35 (unch), CELG: 115.88 (+0.16), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), GILD: 101.90 (+1.10), GWPH: 78.09 (+1.70), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00), AGIO: 118.55 (+0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17)
Epizyme: The Ugly Duckling Of The 2014 Biotech Rally?
Matija Snuderl - at Seeking Alpha - Fri Jan 02, 8:04AM CST
EPZM: 21.58 (+0.08)
Commit To Purchase Epizyme At $15, Earn 11.5% Annualized Using Options
at The Street - Wed Dec 31, 10:43AM CST
Investors eyeing a purchase of Epizyme Inc. stock, but tentative about paying the going market price of $18.73/share, might benefit from considering selling puts among the alternative strategies at their disposal.
EPZM: 21.58 (+0.08)
Epizyme: Shares Oversold On Mixed Data From Early Studies
Poonam A. Arora - at Seeking Alpha - Tue Dec 30, 7:21AM CST
EPZM: 21.58 (+0.08)
Epizyme selects Kenneth Bate to board
M2 - Mon Dec 15, 5:49AM CST
Biopharmaceutical company Epizyme (NasdaqGS:EPZM) revealed on Friday that Kenneth Bate has been named to its board of directors.
EPZM: 21.58 (+0.08), GNCA: 8.93 (-0.07)
Epizyme Elects Kenneth Bate to Board of Directors
Business Wire - Fri Dec 12, 3:01PM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Kenneth Bate, an independent consultant in the biotechnology industry, has been elected to the Company's board of directors.
EPZM: 21.58 (+0.08)
Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial
Business Wire - Mon Dec 08, 12:30PM CST
--Additional biological activity observed: Resolution of cutaneous leukemia in two patients, leukemia cell differentiation effects in eight patients
EPZM: 21.58 (+0.08)
Epizyme First-in-Class PRMT5 Inhibitor Demonstrates In Vitro and In Vivo Activity in Models of Mantle Cell Lymphoma
Business Wire - Mon Dec 08, 12:30PM CST
--First arginine methyltransferase (RMT) inhibitor to show in vitro and in vivo activity in pre-clinical models of mantle cell lymphoma (MCL)
EPZM: 21.58 (+0.08)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 391.66 (-0.45), ISIS: 63.86 (-0.43), OMED: 26.06 (+0.30), GILD: 101.90 (+1.10), TEVA: 56.77 (-0.58), EPZM: 21.58 (+0.08), AGIO: 118.55 (+0.11), SNY: 49.42 (+0.82), FOLD: 8.36 (-0.11), XLRN: 38.02 (+0.07), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16)
Epizyme to Webcast Company Presentation at American Society of Hematology (ASH) Annual Meeting on December 8, 2014
Business Wire - Wed Dec 03, 7:30AM CST
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a live audio webcast of its discussion of the Company's clinical programs and pipeline at the ASH annual meeting on Monday, December 8, 2014, at 12:30 p.m. PT (3:30 p.m. ET).
EPZM: 21.58 (+0.08)
December's Essential, Stock-Moving Biotech Events Explained While Eating Turkey
at The Street - Wed Nov 26, 5:00AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for health care investors.
BLUE: 90.70 (+0.93), OREX: 5.55 (+0.10), BCRX: 10.06 (-0.09), ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), EPZM: 21.58 (+0.08), AGIO: 118.55 (+0.11), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), ENTA: 33.30 (-0.44)
Epizyme Gains on Positive Phase I Data on EPZ-6438 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 5:15PM CST
Epizyme, Inc. (EPZM) announced positive phase I study data on its oncology candidate, EPZ-6438 for advanced solid tumors and B-cell non-Hodgkin lymphomas.
CYTK: 7.78 (+1.29), BIIB: 391.66 (-0.45), EPZM: 21.58 (+0.08)
Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor
Business Wire - Wed Nov 19, 5:01PM CST
--Ongoing partial response seen in one malignant rhabdoid tumor patient, one of two evaluable solid tumor patients with INI1-deficient tumors
EPZM: 21.58 (+0.08)
Nasdaq stocks posting largest percentage decreases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
HTBX: 5.83 (+0.22), TNGO: 12.11 (+0.42), ENPH: 15.15 (+0.37), PRSC: 39.60 (-0.62), MTRX: 19.92 (+0.77), EPZM: 21.58 (+0.08), CHUY: 22.04 (-0.35), AMRI: 16.94 (-0.28), ANDE: 45.11 (+0.71), SNMX: 5.92 (+0.26), ZU: 14.22 (-0.30)
Epizyme drops after cancer drug data underwhelms
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 11:35AM CST
EPZM: 21.58 (+0.08)
